Spots Global Cancer Trial Database for Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy
Official Title: Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy
Study ID: NCT05865301
Conditions
Interventions
Study Description
Brief Summary: To use a consistent and standardized platform to retrospectively and prospectively study children and young adults with B cell malignancies receiving Immunotherapy, blinatumomab and/or inotuzumab ozogamicin.
Detailed Description:
Keywords
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Stanford University, Palo Alto, California, United States
Contact Details
Name: Liora Schultz, M.D
Affiliation: Stanford University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
